KHYG-1 Cells
CAD$690.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | KHYG-1 is a human natural killer (NK) cell leukemia cell line established from the peripheral blood of an adult female patient diagnosed with aggressive NK-cell leukemia. The cell line was derived at initial diagnosis and represents an Epstein-Barr virus (EBV)-negative NK-cell malignancy, distinguishing it from many NK/T-cell lymphoma models that are EBV-associated. KHYG-1 cells grow in suspension and display the cytomorphologic and immunophenotypic characteristics of activated NK cells, including expression of CD56 and cytoplasmic CD3ε, while lacking surface CD3 and T-cell receptor gene rearrangements, consistent with true NK-cell lineage derivation. Molecular profiling studies have included KHYG-1 in genomic and transcriptomic analyses of NK-cell malignancies. Array comparative genomic hybridization and gene expression studies across NK-cell lines have identified recurrent chromosomal abnormalities in NK-cell tumors, such as deletions involving 6q21 and alterations affecting tumor suppressor pathways. In contrast to several EBV-positive NK-cell lines, KHYG-1 does not harbor detectable ATR gene alterations in analyses of the full coding region, underscoring molecular heterogeneity within NK-cell neoplasms. Gene expression profiling places KHYG-1 within the NK-cell lineage cluster, characterized by expression of NK-associated receptors and cytotoxic effector molecules, and distinct from cytotoxic αβ and γδ T-cell lymphomas. Functionally, KHYG-1 exhibits interleukin-2-dependent proliferation in vitro and retains cytotoxic activity typical of NK cells. The line has been widely used to investigate signaling pathways critical to NK-cell survival and proliferation, including aurora kinase A and NOTCH pathway components, as well as to evaluate candidate therapeutic inhibitors targeting NK-cell malignancies. As an EBV-negative model of aggressive NK-cell leukemia, KHYG-1 provides a valuable in vitro system for studying intrinsic oncogenic mechanisms in NK-cell transformation, independent of viral-driven lymphomagenesis. |
|---|---|
| Organism | Human |
| Tissue | Peripheral blood |
| Disease | Natural killer cell lymphoblastic leukemia/lymphoma |
| Synonyms | KHYG1, KHYG |
Characteristics
| Age | 45 years |
|---|---|
| Gender | Female |
| Ethnicity | Japanese |
| Morphology | lymphocyte-like |
| Growth properties | Floating aggregates Cluster |
Regulatory Data
| Citation | KHYG-1 (Cytion catalog number 305890) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_2976 |
Biomolecular Data
| Mutational profile | Mutation: p.Gly12Ala, Unspecified; Mutation: p.Arg248Trp, Unspecified |
|---|
Handling
| Culture Medium | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| Supplements | Supplement the medium with 10% heat-inactivated FBS and 10 ng/ml IL-2 |
| Dissociation Reagent | None |
| Doubling time | 24-48 hours ; ~30-40 hours ; ~54 hours , ~30 hours , ~25 hours |
| Split ratio | Split 1/4 every 3-4 days. |
| Fluid renewal | Simple dilution because of suspension cell culture. Subculture every 3-4 days with split ratio = 1/4. |
| Freeze medium | As a cryopreservation medium, we use complete growth medium + 10% DMSO for adequate post-thaw viability. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
Certificate of Analysis (CoA)
| Lot Number | Certificate Type | Date | Catalog Number |
|---|---|---|---|
| 305890-171125 | Certificate of Analysis | 15. Jan. 2026 | 305890 |